Merrill retains Alizyme at buy

Alizyme was retained by Merrill Lynch analyst Peter Welford at a buy rating after phase 2 data released Monday demonstrated cetilistat has comparable efficacy to other obesity drugs and superior safety and tolerability to Xenical. Merrill said it believes the company will partner on the drug in the first quarter of 2006 prior to phase 3 studies. Shares of the Cambridge, England, drug development company were up 4.50p, or 3.31%, at 140.50p on volume of 4,516,617 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.